Clinical Trial of Atrial Fibrillation Patients Comparing Left Atrial Appendage Occlusion Therapy to Non-vitamin K Antagonist Oral Anticoagulants.
To evaluate the safety and effectiveness of Abbott’s Amplatzer™ Amulet™ Left Atrial Appendage (LAA) occluder device compared to commercially available Novel Oral Anticoagulant (NOAC) drugs in patients with non-valvular atrial fibrillation who are at increased risk for ischemic stroke and systemic embolism and who are recommended for long-term NOAC therapy.
|Eligibility criteria|| |
To be considered for the study you must meet the following criteria:
|Study details|| |
Your participation in this study would be for approximately 5 years.
You will need to attend the clinic for an initial assessment, including medical history and physical examination, ECG, echocardiogram if not performed within the last 6 months and complete questionnaires regarding physical symptoms and quality of life. You will also be required to undertake a neurological assessment at the beginning of the study and during your hospital admission.
Eligible participants will then need to go to hospital to have their clinically indicated catheter ablation procedure. Follow-up assessments will occur before hospital discharge and then at 7 days (phone call), 5 weeks (phone call), 3 months (in-person visit), 6 months (phone call) and 12 months (in-person visit) where you will again be asked about your health and medications, have ECG’s and be asked to complete questionnaires about your quality of life. You will also be provided with a device for trans-telephonic monitoring (TTM) of your heart’s rhythm. You will attach this device to your bare chest and follow the provided instructions to send a transmission of your heart’s rhythm once every 14-days until the 12-month study visit.
There are no additional costs associated with participating, nor will you be paid. All medication, tests and medical care required as part of the study will be provided to you free of charge.
|Further information|| |
For more information regarding this clinical trial click here.